Surrozen Inc.

9.87
-0.13 (-1.30%)
At close: Feb 11, 2025, 3:59 PM
9.70
-1.67%
After-hours Feb 11, 2025, 04:06 PM EST
undefined%
Bid 9
Market Cap 32.06M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -16.94
PE Ratio (ttm) -0.58
Forward PE n/a
Analyst Buy
Ask 11.68
Volume 10,345
Avg. Volume (20D) 44,981
Open 10.05
Previous Close 10.00
Day's Range 9.50 - 10.16
52-Week Range 6.00 - 18.17
Beta undefined

About SRZN

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic...

Industry Biotechnology
Sector Healthcare
IPO Date Jan 11, 2021
Employees 42
Stock Exchange NASDAQ
Ticker Symbol SRZN

Analyst Forecast

According to 2 analyst ratings, the average rating for SRZN stock is "Buy." The 12-month stock price forecast is $38.5, which is an increase of 290.27% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts
1 week ago
+7.29%
Surozen shares are trading higher after HC Wainwri... Unlock content with Pro Subscription
1 month ago
+19.44%
Surrozen shares are trading higher after Guggenheim upgraded the stock from Neutral to Buy.